Difference between revisions of "Bicalutamide (Casodex)"
Jump to navigation
Jump to search
| (26 intermediate revisions by 5 users not shown) | |||
| Line 1: | Line 1: | ||
| − | |||
| − | |||
==General information== | ==General information== | ||
| − | Class/mechanism: Antiandrogen; non-steroidal androgen receptor inhibitor that competitively inhibits androgens by binding to cytosol androgen receptors.<ref name="insert">[ | + | Class/mechanism: Antiandrogen; non-steroidal androgen receptor inhibitor that competitively inhibits androgens by binding to cytosol androgen receptors.<ref name="insert">[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfee4fe7-8478-4a3e-925d-00be3cd0ab67 Bicalutamide (Casodex) package insert]</ref><ref>[[:File:Bicalutamide.pdf | Bicalutamide (Casodex) package insert (locally hosted backup)]]</ref> |
<br>Route: PO | <br>Route: PO | ||
<br>Extravasation: n/a | <br>Extravasation: n/a | ||
| − | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. | + | For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://reference.medscape.com/drug/casodex-bicalutamide-342210 Medscape] [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.<ref name="insert"></ref> |
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| Line 12: | Line 10: | ||
==Patient drug information== | ==Patient drug information== | ||
| − | *[ | + | *[https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=dfee4fe7-8478-4a3e-925d-00be3cd0ab67 Bicalutamide (Casodex) package insert]<ref name="insert"></ref> |
| − | *[ | + | *[https://chemocare.com/druginfo/bicalutamide.aspx Bicalutamide (Casodex) patient drug information (Chemocare)]<ref>[https://chemocare.com/druginfo/bicalutamide.aspx Bicalutamide (Casodex) patient drug information (Chemocare)]</ref> |
*[http://www.uptodate.com/contents/bicalutamide-patient-drug-information Bicalutamide (Casodex) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bicalutamide-patient-drug-information Bicalutamide (Casodex) patient drug information (UpToDate)]</ref> | *[http://www.uptodate.com/contents/bicalutamide-patient-drug-information Bicalutamide (Casodex) patient drug information (UpToDate)]<ref>[http://www.uptodate.com/contents/bicalutamide-patient-drug-information Bicalutamide (Casodex) patient drug information (UpToDate)]</ref> | ||
| + | |||
| + | ==History of changes in FDA indication== | ||
| + | *1995-10-04: Initial accelerated approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced [[prostate cancer]]. ''(Based on Schellhammer et al. 1995)'' | ||
| + | **1997-12-12: Converted to regular approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced [[prostate cancer]]. ''(Based on Schellhammer et al. 1995)'' | ||
| + | ==History of changes in EMA indication== | ||
| + | *1995-02-28: EURD | ||
| + | |||
| + | ==History of changes in Health Canada indication== | ||
| + | *1995-11-02: Initial notice of compliance for use in combination therapy with either a luteinizing hormone releasing hormone (LHRH) analogue or surgical castration in the treatment of metastatic (Stage D2) [[prostate cancer]]. | ||
| + | |||
| + | ==Also known as== | ||
| + | *'''Brand names:''' Bical, Bicalmid, Bicalon, Bicatero, Binarex, Casodex, Cassotide, Cosudex, Calutide, Kalumid, Procalut, Prosmide, Utamide | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| − | [[Category: | + | [[Category:Drugs]] |
| − | [[Category: | + | [[Category:Oral medications]] |
| − | [[Category: | + | |
| + | [[Category:First-generation nonsteroidal antiandrogens]] | ||
| + | |||
[[Category:Prostate cancer medications]] | [[Category:Prostate cancer medications]] | ||
| + | |||
| + | [[Category:FDA approved in 1995]] | ||
| + | [[Category:EMA approved in 1995]] | ||
| + | [[Category:Health Canada approved in 1995]] | ||
| + | [[Category:WHO Essential Cancer Medicine]] | ||
Latest revision as of 01:40, 30 March 2024
General information
Class/mechanism: Antiandrogen; non-steroidal androgen receptor inhibitor that competitively inhibits androgens by binding to cytosol androgen receptors.[1][2]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Bicalutamide (Casodex) package insert[1]
- Bicalutamide (Casodex) patient drug information (Chemocare)[3]
- Bicalutamide (Casodex) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 1995-10-04: Initial accelerated approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced prostate cancer. (Based on Schellhammer et al. 1995)
- 1997-12-12: Converted to regular approval for use in combination therapy with a luteinizing-hormone releasing hormone (LHRH) analogue for the treatment of advanced prostate cancer. (Based on Schellhammer et al. 1995)
History of changes in EMA indication
- 1995-02-28: EURD
History of changes in Health Canada indication
- 1995-11-02: Initial notice of compliance for use in combination therapy with either a luteinizing hormone releasing hormone (LHRH) analogue or surgical castration in the treatment of metastatic (Stage D2) prostate cancer.
Also known as
- Brand names: Bical, Bicalmid, Bicalon, Bicatero, Binarex, Casodex, Cassotide, Cosudex, Calutide, Kalumid, Procalut, Prosmide, Utamide